Tag: Viaskin®
Viaskin Peanut Patch Therapy Delayed Further as DBV Readies Another Phase...
The patch therapy remains in regulatory limbo.
Study: Peanut Immunotherapy Significantly Reduces Risks Due to Cross-Contact in Common...
The study model used common packaged foods such as cookies, ice cream, and doughnuts as references.
Study: EPIT (Skin Patch) Therapy Provides Sustained Protection Against Anaphylaxis
The unique immune communication between skin and gastrointestinal tract can be used to generate long-lasting protection from food allergies.
Nestlé Partners with DBV to Develop Milk Allergy Test
The world's largest food business forays into allergy diagnostic services to help sell infant formula.
Viaskin Peanut, Milk and Egg Patch Therapies: Promising News from the...
We are cautiously optimistic that a safe, effective, easy to administer treatment for food allergy may be on the horizon.
Breakthrough Food Allergy Therapies and the Big Business Behind Them
What it means to be a breakthrough therapy, who is developing them, how they work, and the (big) business drivers behind them.
Viaskin Milk Patch Receives Positive Recommendation to Proceed to Phase II
The board overseeing the Phase I study of the milk allergy therapy found no safety concerns.
